2023-06-09 10:37:00
It is a trial that brings hope for patients. A study conducted by the CHU de Toulouse highlights the effectiveness of a treatment on the lung cancer so-called “poor prognosis”, that is to say whose five-year survival rate is less than 25%. Positive effects were observed for 51.4% of the patients treated: reduction in the size of the tumour, reduction in metastases, reduction in the detectable tumor load or even reduction in tumor markers in the blood.
The clinical trial was conducted from September 2016 to May 2021 on 313 patients, in treatment failure or who had never received treatment before. These patients have a non-small cell lung cancer (CBNPC) and in addition have a genetic mutation that causes “uncontrolled growth of cancer cells” which contributes to aggravating the disease.
Few side effects
Led by the Pr Julien Mazières, pneumo-oncologist at the Toulouse University Hospitalthe study Vision was published on June 4 in the specialized journal JAMA Oncology and presented at the Asco congress, the American Society Clinical Oncology. The treatment used, the tepotinib, targets the protein responsible for the proliferation of cancer cells and thus slows down its progression. Patients received this drug for 18 or 35 months.
The long-term results of Vision are far superior to what is usually observed in the context of conventional chemotherapy treatments”, rejoices the team of researchers.
In addition, other elements observed during the trial make tepotinib a hopeful drug: absence of recurrence under treatment without recurrence for more than a year, duration of response under treatment for more than 18 months, absence of disease progression and few side effects. Note that this Toulouse clinical trial is “the largest in the world on this type of cancer” according to the CHU, which hopes to be at the origin of an “optimal therapeutic approach”.
>> READ ALSO: Toulouse: at the Oncopole, an innovative technique to better target breast cancer
1686309172
#promising #treatment #developed #Toulouse #University #Hospital